Clinical Trials Logo

Hemangiopericytoma clinical trials

View clinical trials related to Hemangiopericytoma.

Filter by:

NCT ID: NCT00464620 Completed - Rhabdomyosarcoma Clinical Trials

Trial of Dasatinib in Advanced Sarcomas

Start date: May 2007
Phase: Phase 2
Study type: Interventional

This study will examine the response rate and the 6-month progression-free survival rates of subjects with advanced sarcoma treated with dasatinib.

NCT ID: NCT00346164 Completed - Clinical trials for Stage IV Adult Soft Tissue Sarcoma

Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma

Start date: February 5, 2007
Phase: Phase 3
Study type: Interventional

This phase III trial is studying observation to see how well a risk based treatment strategy works in patients with soft tissue sarcoma. In the study, patients are assigned to receive surgery +/- radiotherapy +/- chemotherapy depending on their risk of recurrence. Sometimes, after surgery, the tumor may not need additional treatment until it progresses. In this case, observation may be sufficient. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as ifosfamide and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy and radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving these treatments after surgery may kill any tumor cells that remain after surgery.

NCT ID: NCT00045734 Completed - Clinical trials for Recurrent Adult Brain Tumor

Imatinib Mesylate in Treating Patients With Recurrent Meningioma

Start date: February 2003
Phase: Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have recurrent meningioma. Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth